Skip to main content
    E

    Enveric Biosciences Inc (ENVB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.44
    -0.08 (-4.95%)

    Market Cap: $6.78M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Enveric Biosciences Inc (ENVB) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    Enveric Biosciences reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$12.13M, operating cash flow was -$8.14M and free cash flow was -$8.14M. The quarter ended Sep 30, 2026 had net income of -$2.55M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $8.77M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0-100.0%N/AN/AN/A
    Dec 2020$39.91M0.0%-0.3%-14.1%-17.2%
    Dec 2019$39.91M-7.2%20.4%-15.8%-14.0%
    Dec 2018$43.00M-11.5%20.9%-16.6%-39.3%
    Dec 2017$48.59M+34.4%21.1%-24.6%-18.7%
    Dec 2016$36.15MN/A18.1%-14.9%-7.7%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$0$0$0$39.91M$39.91M$43.00M$48.59M$36.15M
    Cost of revenue$200.86K$337.49K$408.03K$435.20K$681.61K$120.87K$31.76M$34.01M$38.36M$29.61M
    Gross profit-$200.86K-$337.49K-$408.03K-$435.20K-$681.61K-$120.87K$8.15M$8.98M$10.24M$6.54M
    Research and development$2.78M$2.84M$7.25M$8.03M$4.79M$174.08K$0$0$0$0
    Operating income-$8.77M-$9.63M-$16.45M-$19.96M-$25.94M-$5.62M-$6.32M-$7.15M-$11.97M-$5.38M
    Net income-$12.13M-$9.57MN/A-$18.50M-$48.98M-$6.86M-$5.60M-$16.90M-$9.07M-$2.78M
    EBITDA-$8.57M-$9.23MN/A-$19.52MN/AN/A-$2.26M-$6.92M-$7.67M-$4.41M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    RevenueN/A$0$0$0$0$0$0$340.38K$0$0$0$647.09K
    Gross profitN/A-$36.83K-$37.24K-$39.48K-$40.37K-$39.98K-$81.02K-$82.49K-$84.81K-$84.78K-$85.41K-$84.68K
    Operating income-$2.56M-$3.03M-$1.63M-$2.19M-$1.87M-$2.52M-$2.19M-$3.17M-$2.08M-$1.90M-$2.48M-$2.38M
    Net income-$2.55M-$3.03M-$1.63M-$2.19M-$1.87M-$2.52M-$2.18M-$3.15M-$2.08M-$1.88M-$2.46M-$3.44M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $4.68M were 91.8% of total assets of $5.10M, against total liabilities of $918.40K.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$5.10M$3.08M$4.30M$19.55M$26.72M$4.10M$25.01M$29.64M$52.20M$39.51M
    Current assets$4.94M$2.73M$3.58M$18.43M$17.74M$2.28M$7.60M$10.06M$14.64M$10.06M
    Cash and equivalents$4.68M$2.24M$2.29M$17.72M$17.36M$1.58M$431.40K$1.37M$4.88M$1.38M
    Total liabilities$918.40K$1.49M$2.34M$4.00M$4.41M$681.25K$14.38M$18.88M$32.75M$27.84M
    Short-term debtN/AN/AN/A$63.82K$107.44K$4.88M$4.88M$5.21M$4.80M$3.49M
    Long-term debtN/AN/AN/AN/AN/AN/AN/AN/A$2.38MN/A
    Shareholder equity$4.18M$1.59M$1.96M$15.56M$22.31M$3.42M$10.62M$10.76M$19.45M$11.66M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$6.37M$8.94M$5.52M$5.10M$4.36M$3.55M$5.10M$3.08M$4.79M$6.05M$8.85M$4.30M
    Total liabilities$644.20K$861.48K$460.68K$918.40K$905.88K$1.36M$1.18M$1.49M$839.17K$645.34K$2.37M$2.34M
    Cash and equivalents$5.61M$8.30M$4.91M$4.68M$3.76M$2.85M$4.29M$2.24M$3.11M$3.50M$6.36M$2.29M
    Shareholder equity$5.73M$8.08M$5.06M$4.18M$3.46M$2.18M$3.92M$1.59M$3.95M$5.41M$6.48M$1.96M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$8.14M-$7.73M-$14.09M-$17.15M-$11.46M-$3.89M-$647.86K-$2.57M-$2.74M-$2.70M
    Capital expenditures$3$0$5.18K$584.16K$864.72K$44.14K$84.33K$189.72K$4.84K$3.69M
    Free cash flow-$8.14M-$7.73M-$14.10M-$17.73M-$12.32M-$3.93M-$732.19K-$2.76M-$2.75M-$6.39M
    Dividends paid$3.36MN/AN/AN/AN/AN/AN/A$2.09T$2.09BN/A
    Investing cash flowN/AN/A$11.67K-$584.16K$2.19M-$44.14K-$284.33K-$3.64M-$808.88K-$6.59M
    Financing cash flow$10.58M$7.67M-$1.34M$18.18M$24.90M$5.53M$560.00K$2.69M$7.05M$8.80M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.65M-$2.44M-$2.26M-$1.78M-$2.07M-$1.89M-$2.39M-$1.31M-$927.07K-$2.89M-$2.60M-$1.75M
    Capital expenditures$0$0$0$0$4$0$0$0$3$3$0$15
    Free cash flow-$2.65M-$2.44M-$2.26M-$1.78M-$2.07M-$1.89M-$2.39M-$1.31M-$927.07K-$2.89M-$2.60M-$1.75M
    Last 12 quarters

    Frequently Asked Questions About ENVB

    What is Enveric Biosciences' annual revenue?

    Enveric Biosciences reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Enveric Biosciences profitable?

    No. Enveric Biosciences reported net income of -$12.13M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does ENVB generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$8.14M minus capital expenditures of $3 produced free cash flow of -$8.14M.

    How much debt does Enveric Biosciences have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $4.68M.